Literature DB >> 8100837

In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

R D Christen1, A P Jekunen, J A Jones, F Thiebaut, D R Shalinsky, S B Howell.   

Abstract

We have previously shown that forskolin and 3-isobutyl-1-methylxanthine (IBMX) increased accumulation of cisplatin (DDP) in DDP-sensitive 2008 human ovarian carcinoma cells in proportion to their ability to increase cAMP. Since the major function of cAMP is to activate protein kinase A, it was conjectured that the stimulation of DDP accumulation was mediated by a protein kinase A substrate. We now show that exposure of 2008 cells to forskolin resulted in phosphorylation of a prominent 52-kD membrane protein. Microsequencing of the band demonstrated it to be human beta-tubulin. Similarly, pretreatment of 2008 cells with the microtubule stabilizing drug taxol increased platinum accumulation in a dose-dependent manner. In 11-fold DDP-resistant 2008/C13*5.25 cells, decreased DDP accumulation was associated with enhanced spontaneous formation of microtubule bundles and decreased expression of beta-tubulin and the tubulin-associated p53 antioncogene relative to 2008 cells. 2008/C13*5.25 cells had altered sensitivity to tubulin-binding drugs, being hypersensitive to taxol and cross-resistant to colchicine. We conclude that pharmacologic alterations of tubulin enhance accumulation of DDP, and that the DDP-resistant phenotype in 2008/C13*5.25 cells is associated with tubulin abnormalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100837      PMCID: PMC293629          DOI: 10.1172/JCI116585

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Phenotypic consequences of tubulin overproduction in Saccharomyces cerevisiae: differences between alpha-tubulin and beta-tubulin.

Authors:  B Weinstein; F Solomon
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

2.  Simian virus 40 large T antigen and p53 are microtubule-associated proteins in transformed cells.

Authors:  S A Maxwell; S K Ames; E T Sawai; G L Decker; R G Cook; J S Butel
Journal:  Cell Growth Differ       Date:  1991-02

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors.

Authors:  P J DiSaia; J G Sinkovics; F N Rutledge; J P Smith
Journal:  Am J Obstet Gynecol       Date:  1972-12-01       Impact factor: 8.661

5.  Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Int J Cancer       Date:  1991-07-30       Impact factor: 7.396

6.  Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro.

Authors:  P Köpf-Maier; S K Mühlhausen
Journal:  Chem Biol Interact       Date:  1992-05       Impact factor: 5.192

7.  cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics.

Authors:  K Boekelheide; M E Arcila; J Eveleth
Journal:  Toxicol Appl Pharmacol       Date:  1992-09       Impact factor: 4.219

8.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.

Authors:  W Zhen; C J Link; P M O'Connor; E Reed; R Parker; S B Howell; V A Bohr
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

9.  Effects of cisplatin on human thyrocytes in monolayer or follicle culture.

Authors:  C Massart; C Le Tellier; C Lucas; J Gibassier; G Leclech; M Nicol
Journal:  J Mol Endocrinol       Date:  1992-06       Impact factor: 5.098

10.  The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin.

Authors:  R Chibber; M J Ord
Journal:  Eur J Cancer Clin Oncol       Date:  1989-01
View more
  14 in total

1.  Inauhzin(c) inactivates c-Myc independently of p53.

Authors:  Ji Hoon Jung; Jun-Ming Liao; Qi Zhang; Shelya Zeng; Daniel Nguyen; Qian Hao; Xiang Zhou; Bo Cao; Sung-Hoon Kim; Hua Lu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Resistance to platinum-based chemotherapy in lung cancer cell lines.

Authors:  Jianli Chen; Nashwa Emara; Charalambos Solomides; Hemant Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-21       Impact factor: 3.333

3.  Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesis.

Authors:  Ali Niapour; Naisana Seyedasli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-02-05       Impact factor: 3.000

Review 4.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

5.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

6.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Authors:  H Parekh; H Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Authors:  P Naredi; D D Heath; R E Enns; S B Howell
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

8.  Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.

Authors:  E Kimura; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Reversal of radiation-induced cisplatin resistance in murine fibrosarcoma cells by selective modulation of the cyclic GMP-dependent transduction pathway.

Authors:  H Eichholtz-Wirth
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

10.  Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo.

Authors:  H Eichholtz-Wirth; B Hietel
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.